Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05430386 | Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC | unknown | Phase 1 | 174 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05715398 | BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 90 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 0 | Feb 10, 2023 |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05416775 | Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 168 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05332574 | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05430009 | Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer | unknown | Phase 1 | 12 | VA Ann Arbor Healthcare SystemFED | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05068024 | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer(FWD1509) | unknown | Phase 1 / Phase 2 | 30 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05273814 | Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT05435274 | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 380 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04052412 | Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer | unknown | Phase 1 | 2 | University of TennesseeOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC(ADIVO Lung) | unknown | Phase 1 / Phase 2 | 53 | National University Hospital, SingaporeOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT05284994 | TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 160 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT05267392 | Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy(IDEAR) | unknown | Phase 1 / Phase 2 | 30 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05223595 | A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC | unknown | Phase 1 | 42 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05157542 | Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC | unknown | Phase 1 | 9 | Juan LI, MDOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT05117138 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | unknown | Phase 1 / Phase 2 | 39 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05079022 | ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | unknown | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT02929290 | Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC | unknown | Phase 1 | 80 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 13, 2021 | clinicaltrials |
| NCT02330367 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC | unknown | Phase 1 / Phase 2 | 368 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Sep 10, 2021 | clinicaltrials |
| NCT05016544 | Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05008861 | Gut Microbiota Reconstruction for NSCLC Immunotherapy | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04990063 | Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 20 | suhaichuanOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04872634 | A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment(SNK_ASTER) | unknown | Phase 1 / Phase 2 | 24 | NKMAX Co., Ltd.INDUSTRY | 1 | Jul 21, 2021 | clinicaltrials |
| NCT02824965 | Pembrolizumab + CVA21 in Advanced NSCLC | unknown | Phase 1 | 11 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04942301 | PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy | unknown | Phase 1 | 24 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 30, 2021 | clinicaltrials |
| NCT01711697 | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 1 | 16 | Emory UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04556669 | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | unknown | Phase 1 | 30 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT03852823 | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours | unknown | Phase 1 | 192 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | unknown | Phase 1 / Phase 2 | 96 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT03976856 | Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib | unknown | Phase 1 | 42 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT02500199 | Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | unknown | Phase 1 | 50 | Hengrui Therapeutics, Inc.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04390984 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | unknown | Phase 1 | 22 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04448379 | Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 | 48 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04667975 | The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy(CKD-702) | unknown | Phase 1 | 74 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04487093 | Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer | unknown | Phase 1 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT04273815 | A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | unknown | Phase 1 / Phase 2 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT03987867 | Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | unknown | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Feb 14, 2023source: clinicaltrials